Trial · NCT03107091
Results by group11
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 11 of 11
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Clinical Safety of Terlipressin Infusion in Cirrhotic Patients With Refractory Ascites | Terlipressin Acetate Continuous Infusion | TEAE | 6 | Participants | |
| Clinical Safety of Terlipressin Infusion in Cirrhotic Patients With Refractory Ascites | Terlipressin Acetate Continuous Infusion | Serious AE | 4 | Participants | |
| Clinical Safety of Terlipressin Infusion in Cirrhotic Patients With Refractory Ascites | Terlipressin Acetate Continuous Infusion | Related TEAE | 3 | Participants | |
| Clinical Safety of Terlipressin Infusion in Cirrhotic Patients With Refractory Ascites | Terlipressin Acetate Continuous Infusion | Serious related TEAE | 0 | Participants | |
| Clinical Safety of Terlipressin Infusion in Cirrhotic Patients With Refractory Ascites | Terlipressin Acetate Continuous Infusion | TEAE leading to drug withdrawal | 3 | Participants | |
| Clinical Safety of Terlipressin Infusion in Cirrhotic Patients With Refractory Ascites | Terlipressin Acetate Continuous Infusion | Grade 3 TEAE | 4 | Participants | |
| Clinical Safety of Terlipressin Infusion in Cirrhotic Patients With Refractory Ascites | Terlipressin Acetate Continuous Infusion | Fatal TEAE | 0 | Participants | |
| Steady State Plasma Levels of Terlipressin and 8-lysine Vasopressin During Terlipressin Continuous Infusion at 2 mg/Day in Cirrhotic Patients With Refractory Ascites | Terlipressin Acetate Continuous Infusion | Terlipressin | 2.48 | Full Range 1.67 to 3.23 | ng/mL |
| Steady State Plasma Levels of Terlipressin and 8-lysine Vasopressin During Terlipressin Continuous Infusion at 2 mg/Day in Cirrhotic Patients With Refractory Ascites | Terlipressin Acetate Continuous Infusion | 8-lysine vasopressin | 0.089 | Full Range 0.07 to 0.138 | ng/mL |
| Change in Requirement of Large Volume Paracentesis With Continuous Infusion of Terlipressin | Terlipressin Acetate Continuous Infusion | Percent change in volume ascites removed during 28d treatment period versus 28d pre-treatment period | -66.5 | Full Range -100.0 to -35.0 | percent change |
| Change in Requirement of Large Volume Paracentesis With Continuous Infusion of Terlipressin | Terlipressin Acetate Continuous Infusion | Percent change in LVP interval during treatment versus before treatment | 128 | Full Range 0 to 414 | percent change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03107091/results